Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)

Article ID	Journal	Published Year	Pages	File Type
6827333	Schizophrenia Research	2012	8 Pages	PDF

Abstract

Use of R-LAI was associated with lower rates of hospitalisation compared to non-use of R-LAI.

Keywords

CGS DSM-IV CGI Schizophrenia Hospitalisation Clinical Global Impressions Long-Acting Injectable Antipsychotics Long-acting injectable antipsychotics Diagnostic and Statistical Manual of Mental Disorders LAI confidence interval Cohort study MINI Mini International Neuropsychiatric Interview

Related Topics

Life Sciences Neuroscience Behavioral Neuroscience

Preview

Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)

Authors

Lamiae Grimaldi-Bensouda, Frederic Rouillon, Bernard Astruc, Michel Rossignol, Jacques Benichou, Bruno Falissard, Frederic Limosin, Beatrice Beaufils, Guillaume Vaiva, Helene Verdoux, Yola Moride, Alban Fabre, Florence Thibaut, Lucien Abenhaim,